In vitro studies by Ji et al. exhibited that ACT has antitumor activity in ESCC by inhibiting the activation of cell division cycle 42 (CDC42) through the HMGB1/RAGE signaling [119]. Here, HMGB1 is linked to esophageal squamous cell carcinoma.